Jazz Pharmaceuticals

What Jazz Pharmaceuticals does

Jazz Pharmaceuticals plc is a global specialty biopharmaceutical company founded in 2003 and headquartered in Dublin, Ireland, with principal executive offices in Palo Alto, California. The company identifies, develops, and commercializes innovative treatments for rare diseases, sleep disorders, epilepsy, and oncology. Its portfolio spans small molecules, biologic therapies (including HER2-targeted bispecific antibodies such as zanidatamab/Ziihera), and cannabinoid-based pharmaceuticals (Epidiolex). Key products include Xywav and Xyrem (oxybate treatments for narcolepsy and idiopathic hypersomnia), Epidiolex (cannabidiol for Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex, achieving blockbuster status at ~$1.1 billion annual revenue), Zepzelca (lurbinectedin for small cell lung cancer), Ziihera (HER2-targeted bispecific antibody for biliary tract cancer), and Modeyso (dordaviprone, FDA accelerated approval August 2025 for H3 K27M-mutant diffuse midline glioma). The company has grown significantly through strategic acquisitions including GW Pharmaceuticals ($7.2 billion in 2021) and Chimerix (2025-2026).

Jazz operates a specialty pharmaceutical business model with prescription-based drug pricing managed through specialty pharmacies, commercial insurance, Medicare Part D, and patient assistance programs. The go-to-market motion is sales-led, deploying specialty sales representatives and medical science liaisons who engage physicians and healthcare providers directly, supplemented by participation in major medical conferences (ASCO, SLEEP, AACR). Distribution flows through specialty pharmacy networks with specialized handling requirements. The company holds manufacturing operations in Athlone, Ireland and Villa Guardia, Italy (Gentium S.r.l.), and maintains commercial offices across the US, Canada, UK, Ireland, France, Germany, Italy, Spain, and the Nordics.

Jazz serves patients with rare and serious conditions — narcolepsy, idiopathic hypersomnia, treatment-resistant epilepsies, HER2-positive gastrointestinal and biliary tract cancers, small cell lung cancer, and H3 K27M-mutant diffuse midline glioma — where unmet medical need is high and therapeutic alternatives are limited. The company generated record FY2025 revenue of $4.3 billion (its 21st consecutive year of top-line growth) and $1.07 billion in Q1 2026 (+19% YoY), with 2026 guidance of $4.25-$4.50 billion. The market capitalization reached approximately $15 billion by May 2026, supported by strong unit economics including 85.2% ROIC and 277.4% YoY EPS growth.

Name

Jazz Pharmaceuticals

Legal name

Jazz Pharmaceuticals plc

Website

https://jazzpharma.com

Company type

Public

Founded year

2003

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Jazz Pharmaceuticals is a global specialty biopharmaceutical company developing and commercializing treatments for rare diseases, sleep disorders, epilepsy, and oncology. Key franchises include Xywav, Epidiolex, Zepzelca, Ziihera, and Modeyso, serving patients with high unmet medical need.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

akta.pro secondary industries

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF), Gastroenterology Specialty Pharmaceuticals (HLAIACAE), Hematology Specialty Pharmaceuticals (Non-malignant) (HLAIACAI)

Keywords

• Specialty pharmaceuticals
• Rare disease therapies
• Epilepsy medications
• Oncology biologics
• Sleep disorder treatments

Headquarters

HQ city

Palo Alto

HQ country

United States

HQ region

North America

Offices11 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Neuroscience/Sleep Franchise: Revenue from sleep disorder treatments including Xywav and Xyrem (narcolepsy, idiopathic hypersomnia), representing significant portion of company revenue with strong market position
2. Epilepsy Franchise: Sales of Epidiolex (cannabidiol) for severe forms of epilepsy including Dravet syndrome and Lennox-Gastaut syndrome, achieving blockbuster status with $1.1 billion annual revenue
3. Oncology Products: Revenue from Zepzelca (lurbinectedin), Ziihera (zanidatamab), Rylaze, Vyxeos, and Defitelio across multiple cancer indications
4. Modeyso: Recently launched product (FDA accelerated approval August 2025) for H3 K27M-mutant diffuse midline glioma, generating $37-48 million in early quarters
5. Debt Financing and Equity: Capital raises through senior notes and exchangeable senior notes for debt prepayment, share repurchases, and general corporate purposes

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Jazz Pharmaceuticals is a global biopharmaceutical company that identifies, develops, and commercializes specialty pharmaceutical products for rare diseases, sleep disorders, epilepsy, and oncology. Its portfolio includes FDA-approved medicines such as Xywav (low-sodium oxybate) and Xyrem for narcolepsy, Epidiolex (cannabidiol) for severe childhood-onset epilepsies, Zepzelca and Ziihera for oncology, Rylaze and Vyxeos for hematologic cancers, Defitelio for hepatic veno-occlusive disease, Sunosi for sleep-related wakefulness, and Modeyso for H3 K27M-mutant diffuse midline glioma. The company manufactures these therapies in Ireland and Italy and distributes them globally via specialty pharmacies.

Product overview

Jazz Pharmaceuticals is a global biopharmaceutical company with a diversified portfolio of branded pharmaceutical products spanning sleep disorders, epilepsy, and oncology. The core product portfolio includes: Xywav and Xyrem (oxyate treatments for narcolepsy); Epidiolex (cannabidiol for epilepsy); Zepzelca (lung cancer treatment); Ziihera (HER2-targeted antibody for biliary tract and gastroesophageal cancers); Rylaze (leukemia treatment); Vyxeos (AML therapy); Defitelio (hepatic VOD treatment); Sunosi (wakefulness agent); and Modeyso (brain cancer treatment). The company focuses on rare diseases with limited or no therapeutic options.

Differentiator

Problem solved

Functional benefit

Products and services

• Xywav (calcium, magnesium, potassium, and sodium oxybates) Low-sodium oxybate oral solution for the treatment of cataplexy and excessive daytime sleepiness in narcolepsy and idiopathic hypersomnia in adult and pediatric patients aged 7 and older.
• Xyrem (sodium oxybate) Original sodium oxybate oral solution approved for the treatment of cataplexy and excessive daytime sleepiness in narcolepsy patients 7 years of age and older.
• Epidiolex (cannabidiol) FDA-approved plant-derived cannabidiol oral solution for seizures associated with Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex in patients 1 year of age and older.
• Zepzelca (lurbinectedin) Alkylating oncology agent approved for adult patients with metastatic small cell lung cancer that has progressed on or after platinum-based chemotherapy, including first-line maintenance use.
• Ziihera (zanidatamab-hrii) HER2-directed bispecific antibody for the treatment of previously treated unresectable locally advanced or metastatic HER2-positive biliary tract cancer, with regulatory progress toward first-line HER2-positive gastroesophageal adenocarcinoma.
• Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) Recombinant Erwinia asparaginase used as a component of multi-agent chemotherapy regimens for the treatment of acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma in adult and pediatric patients who have developed hypersensitivity to E. coli-derived asparaginase.
• Vyxeos (daunorubicin and cytarabine) Liposomal formulation of daunorubicin and cytarabine indicated for the treatment of newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
• Defitelio (defibrotide sodium) Defibrotide sodium approved for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD) with renal or pulmonary dysfunction following hematopoietic stem cell transplantation (HSCT).
• Sunosi (solriamfetol) Wakefulness-promoting agent approved to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA).
• Modeyso (dordaviprone) Small molecule therapy granted FDA accelerated approval in August 2025 for adult and pediatric patients with H3 K27M-mutant diffuse midline glioma, a rare and aggressive brain cancer.

Quantifiable outcome

• Ziihera (zanidatamab) demonstrated median progression-free survival of 12.4 months vs 8.1 months (HR 0.63-0.65) and median overall survival of 26.4 months vs 19.2 months (HR 0.72) in HER2+ gastroesophageal adenocarcinoma
• +4 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• AbCellera BiologicscoreStrategic or Co-development Partner · 17 June 2026Preclinical research collaboration, option and license agreement to discover and develop next-generation T-cell engaging multispecific antibodies targeting gastrointestinal cancers and solid tumors. AbCellera receives $56 million upfront for first two programs, $28 million for third program, and up to $792 million per program in option fees and milestone payments plus tiered royalties on net sales. Jazz receives exclusive worldwide development and commercialization rights.
• BeOne MedicinescoreStrategic or Co-development Partner · 29 April 2026Collaboration on TEVIMBRA (tislelizumab) in combination with ZIIHERA for first-line HER2+ gastroesophageal adenocarcinoma. FDA granted Priority Review and Breakthrough Therapy Designation to the combination regimen. BEOne holds rights to TEVIMBRA while Jazz holds rights to ZIIHERA (zanidatamab).
• American Nutrition AssociationminorStrategic or Co-development Partner · 24 March 2026Collaborative initiative to promote evidence-based nutritional education focusing on sodium reduction for people with narcolepsy or idiopathic hypersomnia. The partnership aims to translate nutrition science into actionable guidance for patients and healthcare providers.
• CNX TherapeuticsminorChannel Partner/ Reseller/ Distributor · 1 November 2025Acquisition of Sativex (nabiximols) from Jazz Pharmaceuticals plc by UK-based specialty pharmaceutical firm CNX Therapeutics to expand CNX's central nervous system portfolio with plant-based treatment for muscle spasticity in multiple sclerosis patients.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Avadel Pharmaceuticals: Avadel developed Lumryz (FT218), a once-nightly sodium oxybate for narcolepsy that directly competes with Jazz's Xyrem franchise. Avadel's legal and commercial dispute with Jazz over REMS-related patents makes them a head-to-head competitor in the oxybate/sleep disorder space.
• Vertex Pharmaceuticals: Vertex is a leading specialty biopharma with a portfolio focused on serious diseases, including a sleep franchise (Truvada/DAYBUE timeline) and rare disease leadership in cystic fibrosis. Both companies operate a specialty pharma model targeting rare and serious conditions with proprietary, differentiated therapeutics, making them highly comparable on business model, GTM motion, and therapeutic focus on CNS and rare diseases.
• Insmed: Insmed is a specialty biopharma focused on rare diseases (e.g., ARIKAYCE, brensocatib) with a similar commercialization model targeting underserved patient populations through specialty distribution and physician education. Both companies leverage rare disease regulatory pathways and orphan drug exclusivity to support pricing.
• BioMarin Pharmaceutical: BioMarin is a rare disease specialty biopharma with a portfolio of branded orphan drugs across multiple therapeutic areas. Jazz's rare disease, orphan-drug commercial model (Xywav, Epidiolex, Modeyso) closely mirrors BioMarin's approach to monetizing small patient populations with high-priced specialty therapeutics.
• UCB: UCB is a Belgian specialty biopharma with a strong CNS and epilepsy franchise (Vimpat, Briviact, Keppra). Jazz's Epidiolex competes in similar severe epilepsy indications, and both companies target CNS specialty markets with branded innovation and global commercialization infrastructure.
• Catalyst Pharmaceuticals: Catalyst Pharmaceuticals is a specialty pharma focused on rare neurological and metabolic diseases (e.g., FIRDAPSE for LEMS, AGAMREE for DMD). Their commercial strategy of targeting rare diseases with limited treatment options through specialty sales forces closely mirrors Jazz's model in sleep and rare oncology.
• Harmony Biosciences: Harmony Biosciences commercializes Wakix (pitolisant) for narcolepsy, directly competing with Jazz's Xywav and Xyrem in the same sleep disorder specialty market. Both companies target rare sleep/neurology indications through specialty pharmacy distribution and medical science liaison engagement.
• Ultragenyx Pharmaceutical: Ultragenyx is a rare disease specialist developing and commercializing therapies for serious genetic and metabolic disorders. Both companies emphasize orphan drug designation, accelerated approval pathways, and specialty pharmacy distribution, with comparable GTM models targeting small but high-value patient populations.

Broad incumbents

• Takeda Pharmaceutical: Takeda operates a broad rare disease and specialty franchise through its Rare Diseases and Oncology business units, including products that overlap with Jazz's portfolio areas (CNS, hematology). While much larger and more diversified, Takeda's rare disease commercial approach overlaps with Jazz's specialty pharma playbook.
• Alexion (AstraZeneca Rare Disease): Alexion, now part of AstraZeneca, is a leading rare disease franchise with Soliris/Ultomiris and Strensiq. Its specialty pharma model targeting ultra-rare, high-priced indications with global commercial reach directly parallels Jazz's rare disease GTM approach, though Alexion operates at significantly larger scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/160408433982020
• LinkedInlinkedin.com/company/jazz-pharmaceuticals

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries4 records

Funding overview

Funding rounds8 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A10 records

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Jazz Pharmaceuticals